Howard Fillit
Co-Founder and Chief Science Officer @ Alzheimer's Drug Discovery Foundation
New York, United States
Howard Fillit is a grant investor at Alzheimer's Drug Discovery Foundation in New York focused on Biotechnology and Health Care. Howard Fillit is based out of New York, New York, and is the Co-Founder and Chief Science Officer of Alzheimer's Drug Discovery Foundation. Howard previously worked at New York Life Insurance Company as a Corporate Medical Director for Medicare. Howard Fillit attended Cornell University. Howard Fillit has received the Award for The RitaHayworth.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 85%
Last updated:
For AI agents: llms.txt
Industries Howard Fillit invests in
Stages Howard Fillit invests in
Countries Howard Fillit invests in
Investment Focus
Industry
- Biotechnology 10 (77%)
- Health Care 7 (54%)
- Medical 5 (38%)
- Life Science 3 (23%)
- Pharmaceutical 3 (23%)
Stage
- Grant 4 (31%)
- Venture - Series Unknown 3 (23%)
- Series A 2 (15%)
- Seed 1 (8%)
- Series B 1 (8%)
Country
- United States 7 (54%)
- Canada 2 (15%)
- Taiwan 1 (8%)
- Denmark 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Circular Genomics
|
Circular Genomics develops circular RNA (circRNA)-based diagnostic and biomarker tools for neurological and psychiatric disorders. The company uses brain-derived circRNAs, a class of stable non-coding RNA molecules enriched in the brain, to build blood-based assays that reflect disease biology in real time. Its first product, MindLight™, predictswhether a patient with major depressive disorder will respond to SSRI antidepressants. Circular Genomics is also creating additional assays designed for early detection and risk prediction of neurodegenerative diseases such as Alzheimer’s disease. The company applies its circRNA platform to help clinicians make more informed treatment decisions using molecular indicators of brain health. | $250K / Grant / Jul 08, 2025 | |
GLX Analytix
|
GLX Analytix is a biomedical company that develops a new technology to identify a biomarker. The company was founded in 2019 and is based in Copenhagen, Denmark. | Venture - Series Unknown / Oct 29, 2024 | |
Imeka
|
Provider of brain imaging platform created to help researchers get the most out of their medical images. The company's platform offers MRI high standing structure and deep learning algorithms, enabling pharmaceutical companies to quantity and understand brain connectivity and white matter. | Grant / Oct 24, 2023 | |
APRINOIA Therapeutics
|
APRINOIA is a late-stage biotechnology company committed to protecting patients' brain health and changing outcomes of neurodegenerative diseases through first-in-class and best-in-class diagnostic tools and novel therapies. The company aims to bring precision medicine to neuroscience by identifying and targeting the protein aggregates of tau,alpha-synuclein and other proteins that play a critical role in the pathogenesis of many neurodegenerative diseases, such as Alzheimer's and Parkinson's Diseases. The company currently has operations in Hong Kong, Suzhou, Shanghai, Tokyo, and Boston. | $4.4M / Venture - Series Unknown / Sep 11, 2023 | |
Astrocyte Pharmaceuticals
|
Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease. | $6M / Series B / Aug 18, 2023 | |
Therini Bio
|
Therini Bio is dedicated to the research and development of novel therapeutics for the treatment of neurological diseases. The company's approach is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation. | $36M / Series A / Apr 27, 2023 | |
Superfluid Dx
|
Tissue-specific cell-free circulating RNA is a newly developed area for molecular diagnosis. Based on this powerful non-invasive approach, Molecular Stethoscope aims to transform healthcare by providing early insight into a patient’s healthy versus disease state. | Grant / Jun 07, 2022 | |
|
Superfluid Dx
|
Tissue-specific cell-free circulating RNA is a newly developed area for molecular diagnosis. Based on this powerful non-invasive approach, Molecular Stethoscope aims to transform healthcare by providing early insight into a patient’s healthy versus disease state. | Grant / Jun 07, 2022 | |
Quanterix
|
Quanterix Corporation is developing a novel platform for single-molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research. Their unique approach permits rapid quantification and analysis of individual proteins and small moleculeswithin complex biological samples, enabling us to address a variety of unmet medical needs. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’s technology is designed to enable much earlier disease detection, better prognosis, and precise treatment methods to improve the quality of life and longevity of the population for generations to come. | Grant / Mar 29, 2022 | |
Optina Diagnostics
|
Optina Diagnostics develops technology for the early detection of disease through the eye. | $2.1M / Jan 24, 2022 | |
| See all 13 investments → | |||
Co-Investors
MRL Ventures Fund
2 deals together
Sanofi Ventures
2 deals together
SV Health Investors
2 deals together
Alzheimer's Drug Discovery Foundation
1 deal together
Boston Harbor Angels
1 deal together
About Alzheimer's Drug Discovery Foundation
The Alzheimer’s Drug Discovery Foundation (ADDF) is the only public charity solely dedicated to finding effective drugs for Alzheimer’s disease. Our pioneering biomedical venture philanthropy approach allows us to invest in the most promising drug discovery and development programs around the world in both academic institutions andbiopharmaceutical companies. Since our founding in 1998, the ADDF has invested nearly $100 million to support over 500 programs across 18 countries.
Alzheimer's Drug Discovery Foundation Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Howard Fillit
Co-Founder and Chief Science Officer
|
|||
Leonard Lauder
Co-Chairman & Co-Founder
|
|||
Martin Tolar
Business Advisory Board & Scientific Review Board
|
|||
Meriel Owen
Director
|
|||
|
Ronald S. Lauder
Co-Chairman and Co-Founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Howard Fillit invest in?
Howard Fillit invests primarily in Biotechnology, Health Care and Medical startups, most often at Grant and Venture - Series Unknown stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Howard Fillit last invest?
The most recent investment recorded for Howard Fillit closed in Jul 2025. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
